Glaxo Loses Patent For Seretide/Advair In U.K.

Law360, New York (March 19, 2004, 12:00 AM EST) -- GlaxoSmithKline has lost a U.K. patent challenge from generic drug makers Cipla and Ivax on its top-selling athma drug Seretide (Advair).

Justice Pumfrey with the High Court ruled Friday that the patent for Seretide was “entirely obvious” and invalidated it.

Glaxo said it was considering whether to appeal the decision.

The case rested on whether Glaxo’s scientists took a truly inventive step in combining two older drugs, Flovent and Serevent, to make Seretide.

Cipla and Ivax had argued that the patent for the inhaled asthma treatment,...
To view the full article, register now.